Limited options are available for clozapine-resistant schizophrenia and intolerable side effects ... more Limited options are available for clozapine-resistant schizophrenia and intolerable side effects of clozapine. We conducted a systematic review of randomized-controlled trials (RCTs) to determine the efficacy and safety of aripiprazole augmentation of clozapine for schizophrenia. Electronic databases searched included PubMed, Scopus, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science. This review synthesized the data of four short-term (8-24 weeks), placebo-controlled trials (N = 347). The overall relative risk (RR, 95% confidence interval) of discontinuation rates was not significantly different between groups (RR = 1.41, 95% CI = 0.78 to 2.56). The pooled standardized mean differences (SMDs, 95% CIs) (Z-test; number of study; I(2)-index) suggested trends of aripiprazole augmentation benefits on overall psychotic [-0.40 (-0.87 to 0.07) (n = 3; Z = 1.68, p = 0.09; I(2) = 68%)], positive [-1.05 (-2.39 to 0.29) (n = 3; Z = 1.54, p = 0.12; I(2) = 94%)], and negative [-0.36 (-0.77 to 0.05) (n = 3; Z = 1.74, p = 0.08; I(2) = 54%)] symptoms. Despite of no benefit on three cardiometabolic indices (i.e., fasting plasma glucose, triglyceride, and high-density lipoprotein), aripiprazole augmentation was superior for weight change with a mean difference (95% CI) of -1.36 kg (-2.35 to -0.36) (n = 3; Z = 2.67, p = 0.008; I(2) = 39%) and LDL-cholesterol with a mean difference of -11.06 mg/dL (-18.25 to -3.87) (n = 3; Z = 3.02, p = 0.003; I(2) = 31%). Aripiprazole augmentation was not correlated with headache and insomnia but significantly associated with agitation/akathesia (RR = 7.59, 95% CI = 1.43 to 40.18) (n = 3; Z = 2.38, p = 0.02; I(2) = 0%) and anxiety (RR = 2.70, 95% CI = 1.02 to 7.15) (n = 1; Z = 2.00, p = 0.05). The limited short-term data suggested that aripiprazole augmentation of clozapine can minimize the cardiometabolic risk, causes agitation/akathesia, and may be effective in attenuating psychotic symptoms.
Recent studies have promised that lisdexamfetamine (LDX) is effective in the treatment of adults ... more Recent studies have promised that lisdexamfetamine (LDX) is effective in the treatment of adults with attention-deficit hyperactivity disorder (ADHD). This systematic review was undertaken to summarize LDX efficacy, acceptability, and tolerability in adult ADHD. All randomized controlled trials (RCTs) of lisdexamfetamine compared with placebo were included for synthesis. Clinical trials published between January 1991 and January 2014 were evaluated. The database of MEDLINE(®), EMBASE™, CINAHL(®), PsycINFO(®) and Cochrane Controlled Trials Register were searched in January 2014. Studies were also searched in ClinicalTrials.gov and the EU Clinical Trials Register database. Study eligibility criteria, participants, and interventions were considered. All RCTs of LDX vs placebo reporting final results of: 1) severity of ADHD symptoms and executive function deficit, 2) response or remission rates, 3) overall discontinuation rate, or 4) discontinuation rate due to adverse events were inclu...
The bias and accuracy of three simple methods for predicting lithium doses were assessed in this ... more The bias and accuracy of three simple methods for predicting lithium doses were assessed in this prospective study. In each patient, we computed the predicted doses (PDs) of lithium by applying three formulas. The actual dose (AD), the lowest lithium dose that was enough to produce a serum lithium concentration higher than 0.80 mmol/l, was determined. The PD computed by each formula was then compared with the AD to identify the one with the least bias and the greatest accuracy in predicting therapeutic lithium doses. As mean prediction error (ME) is a convenient measure of bias, the prediction error (PE) of each comparison was computed by subtracting the AD from the PD. Accuracy was assessed as a function of the root-mean-squared prediction error (rMSE). Seventeen psychiatric inpatients participated in this study. The 95% confidence interval of ME of a proposed formula [Zetin, M., Garber, D., De Antonio, M., Schlegel, A., Feureisen, S., Fieve, R., Jewett, C., Reus, V., Huey, L.Y., 1986. Prediction of lithium dose: a mathematic alternative to the test-dose method. Journal of Clinical Psychiatry 47, 175-178] was across zero (-15.48 to 133.72). In addition, the rMSE of that formula was also the lowest one (152.66 mg/day). The method proposed by Zetin et al. (1986) is the least biased and the most accurate way to predict therapeutic lithium doses.
Conclusion: According to the present review, LDX was effective and well-tolerated in the treatmen... more Conclusion: According to the present review, LDX was effective and well-tolerated in the treatment of child and adolescent ADHD.
Limited options are available for clozapine-resistant schizophrenia and intolerable side effects ... more Limited options are available for clozapine-resistant schizophrenia and intolerable side effects of clozapine. We conducted a systematic review of randomized-controlled trials (RCTs) to determine the efficacy and safety of aripiprazole augmentation of clozapine for schizophrenia. Electronic databases searched included PubMed, Scopus, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science. This review synthesized the data of four short-term (8-24 weeks), placebo-controlled trials (N = 347). The overall relative risk (RR, 95% confidence interval) of discontinuation rates was not significantly different between groups (RR = 1.41, 95% CI = 0.78 to 2.56). The pooled standardized mean differences (SMDs, 95% CIs) (Z-test; number of study; I(2)-index) suggested trends of aripiprazole augmentation benefits on overall psychotic [-0.40 (-0.87 to 0.07) (n = 3; Z = 1.68, p = 0.09; I(2) = 68%)], positive [-1.05 (-2.39 to 0.29) (n = 3; Z = 1.54, p = 0.12; I(2) = 94%)], and negative [-0.36 (-0.77 to 0.05) (n = 3; Z = 1.74, p = 0.08; I(2) = 54%)] symptoms. Despite of no benefit on three cardiometabolic indices (i.e., fasting plasma glucose, triglyceride, and high-density lipoprotein), aripiprazole augmentation was superior for weight change with a mean difference (95% CI) of -1.36 kg (-2.35 to -0.36) (n = 3; Z = 2.67, p = 0.008; I(2) = 39%) and LDL-cholesterol with a mean difference of -11.06 mg/dL (-18.25 to -3.87) (n = 3; Z = 3.02, p = 0.003; I(2) = 31%). Aripiprazole augmentation was not correlated with headache and insomnia but significantly associated with agitation/akathesia (RR = 7.59, 95% CI = 1.43 to 40.18) (n = 3; Z = 2.38, p = 0.02; I(2) = 0%) and anxiety (RR = 2.70, 95% CI = 1.02 to 7.15) (n = 1; Z = 2.00, p = 0.05). The limited short-term data suggested that aripiprazole augmentation of clozapine can minimize the cardiometabolic risk, causes agitation/akathesia, and may be effective in attenuating psychotic symptoms.
Recent studies have promised that lisdexamfetamine (LDX) is effective in the treatment of adults ... more Recent studies have promised that lisdexamfetamine (LDX) is effective in the treatment of adults with attention-deficit hyperactivity disorder (ADHD). This systematic review was undertaken to summarize LDX efficacy, acceptability, and tolerability in adult ADHD. All randomized controlled trials (RCTs) of lisdexamfetamine compared with placebo were included for synthesis. Clinical trials published between January 1991 and January 2014 were evaluated. The database of MEDLINE(®), EMBASE™, CINAHL(®), PsycINFO(®) and Cochrane Controlled Trials Register were searched in January 2014. Studies were also searched in ClinicalTrials.gov and the EU Clinical Trials Register database. Study eligibility criteria, participants, and interventions were considered. All RCTs of LDX vs placebo reporting final results of: 1) severity of ADHD symptoms and executive function deficit, 2) response or remission rates, 3) overall discontinuation rate, or 4) discontinuation rate due to adverse events were inclu...
The bias and accuracy of three simple methods for predicting lithium doses were assessed in this ... more The bias and accuracy of three simple methods for predicting lithium doses were assessed in this prospective study. In each patient, we computed the predicted doses (PDs) of lithium by applying three formulas. The actual dose (AD), the lowest lithium dose that was enough to produce a serum lithium concentration higher than 0.80 mmol/l, was determined. The PD computed by each formula was then compared with the AD to identify the one with the least bias and the greatest accuracy in predicting therapeutic lithium doses. As mean prediction error (ME) is a convenient measure of bias, the prediction error (PE) of each comparison was computed by subtracting the AD from the PD. Accuracy was assessed as a function of the root-mean-squared prediction error (rMSE). Seventeen psychiatric inpatients participated in this study. The 95% confidence interval of ME of a proposed formula [Zetin, M., Garber, D., De Antonio, M., Schlegel, A., Feureisen, S., Fieve, R., Jewett, C., Reus, V., Huey, L.Y., 1986. Prediction of lithium dose: a mathematic alternative to the test-dose method. Journal of Clinical Psychiatry 47, 175-178] was across zero (-15.48 to 133.72). In addition, the rMSE of that formula was also the lowest one (152.66 mg/day). The method proposed by Zetin et al. (1986) is the least biased and the most accurate way to predict therapeutic lithium doses.
Conclusion: According to the present review, LDX was effective and well-tolerated in the treatmen... more Conclusion: According to the present review, LDX was effective and well-tolerated in the treatment of child and adolescent ADHD.
Uploads
Papers by Narong Maneeton
Read this original research and sign up to receive Drug Design, Development and Therapy journal here: http://www.dovepress.com/articles.php?article_id=21120
Read this original research and sign up to receive Drug Design, Development and Therapy journal here: http://www.dovepress.com/articles.php?article_id=21120